# FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors

Study · id `cardio:ct-nct07181135` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07181135](<https://clinicaltrials.gov/study/NCT07181135>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07181135

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 180 participants.

## Technical summary

Registry record NCT07181135. Randomized; double masking; primary purpose treatment. Start 2026-03-13 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT07181135, source copy `cardio:ctgov-nct07181135-2026-04-14`, retrieved 2026-10-26)
- Started: 2026-03-13 (actual) (ClinicalTrials.gov record NCT07181135, source copy `cardio:ctgov-nct07181135-2026-04-14`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07181135, source copy `cardio:ctgov-nct07181135-2026-04-14`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07181135, source copy `cardio:ctgov-nct07181135-2026-04-14`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT07181135, source copy `cardio:ctgov-nct07181135-2026-04-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07181135-2026-04-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors
- Acronym: FINE-START
- Condition: Chronic Kidney Disease
- Intervention (Drug): Finerenone (BAY 94-8862)
- Intervention (Drug): Placebo
- Lead sponsor: University Medical Center Groningen
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as the lead sponsor: University Medical Center Groningen (`cardio:org-university-medical-center-groningen`)

## Provenance

Content hash: 17eeaeacbb9af12bd6394d50129a3a3aea15d162b5b99e54e9afc1fee7348540
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
